Figure 5

TTP and RFS (starting from primary treatments rather than baseline radiographic tumour assessments) of patients treated with DC vaccine during the trial period and 4-year follow-up study in comparison with historical controls ( n =31). The composition of 31 patients with HCC for historical control group was summarised in Table 5. A statistically significant difference in survival was noted (P<0.05).